These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32366290)

  • 81. Gene therapy for ALI/ARDS.
    Lin X; Dean DA
    Crit Care Clin; 2011 Jul; 27(3):705-18. PubMed ID: 21742224
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Mesenchymal Stem Cells (MSCs) as a Potential Therapeutic Strategy in COVID-19 Patients: Literature Research.
    Coelho A; Alvites RD; Branquinho MV; Guerreiro SG; Maurício AC
    Front Cell Dev Biol; 2020; 8():602647. PubMed ID: 33330498
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Mesenchymal stem cells in acute lung injury: are they ready for translational medicine?
    Xu F; Hu Y; Zhou J; Wang X
    J Cell Mol Med; 2013 Aug; 17(8):927-35. PubMed ID: 23834470
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Novel interventional approaches for ALI/ARDS: cell-based gene therapy.
    Zhu YG; Qu JM; Zhang J; Jiang HN; Xu JF
    Mediators Inflamm; 2011; 2011():560194. PubMed ID: 21785528
    [TBL] [Abstract][Full Text] [Related]  

  • 85. pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury.
    Chen MC; Lai KS; Chien KL; Teng ST; Lin YR; Chao W; Lee MJ; Wei PL; Huang YH; Kuo HP; Weng CM; Chou CL
    Front Immunol; 2022; 13():871828. PubMed ID: 35585988
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mesenchymal stem cells and acute lung injury.
    Gotts JE; Matthay MA
    Crit Care Clin; 2011 Jul; 27(3):719-33. PubMed ID: 21742225
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Research progress of mesenchymal stem cells attenuating acute respiratory distress syndrome by regulating the balance of M1/M2 macrophage polarization].
    Zheng L; Wang S; Yang H; Lyu X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Apr; 33(4):509-512. PubMed ID: 34053502
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Stem cell therapy in coronavirus disease 2019: current evidence and future potential.
    Shetty R; Murugeswari P; Chakrabarty K; Jayadev C; Matalia H; Ghosh A; Das D
    Cytotherapy; 2021 Jun; 23(6):471-482. PubMed ID: 33257213
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to clinic.
    Zhuang X; Jiang Y; Yang X; Fu L; Luo L; Dong Z; Zhao J; Hei F
    Front Immunol; 2023; 14():1244930. PubMed ID: 37711624
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors.
    Lee JW; Fang X; Krasnodembskaya A; Howard JP; Matthay MA
    Stem Cells; 2011 Jun; 29(6):913-9. PubMed ID: 21506195
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury.
    Vaka R; Khan S; Ye B; Risha Y; Parent S; Courtman D; Stewart DJ; Davis DR
    Stem Cell Res Ther; 2022 Jan; 13(1):20. PubMed ID: 35033181
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cell-derived biomimetic nanoparticles for the targeted therapy of ALI/ARDS.
    Gao R; Lin P; Fang Z; Yang W; Gao W; Wang F; Pan X; Yu W
    Drug Deliv Transl Res; 2024 Jun; 14(6):1432-1457. PubMed ID: 38117405
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.
    Du J; Li H; Lian J; Zhu X; Qiao L; Lin J
    Stem Cell Res Ther; 2020 May; 11(1):192. PubMed ID: 32448377
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Mesenchymal Stem/Stromal Cells Therapy for Sepsis and Acute Respiratory Distress Syndrome.
    Byrnes D; Masterson CH; Artigas A; Laffey JG
    Semin Respir Crit Care Med; 2021 Feb; 42(1):20-39. PubMed ID: 32767301
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Mesenchymal stem cells: Therapeutic option in ARDS, COPD, and COVID-19 patients].
    Martínez-Zarco BA; Jiménez-García MG; Tirado R; Ambrosio J; Hernández-Mendoza L
    Rev Alerg Mex; 2023 Jun; 70(2):89-101. PubMed ID: 37566772
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Molecular Mechanisms of Vascular Damage During Lung Injury.
    Bossardi Ramos R; Adam AP
    Adv Exp Med Biol; 2021; 1304():95-107. PubMed ID: 34019265
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinical review: gene-based therapies for ALI/ARDS: where are we now?
    Devaney J; Contreras M; Laffey JG
    Crit Care; 2011; 15(3):224. PubMed ID: 21699743
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome.
    Liu C; Xiao K; Xie L
    Front Cell Dev Biol; 2022; 10():951764. PubMed ID: 36036014
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical review: Stem cell therapies for acute lung injury/acute respiratory distress syndrome - hope or hype?
    Hayes M; Curley G; Ansari B; Laffey JG
    Crit Care; 2012 Dec; 16(2):205. PubMed ID: 22424108
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Research progress of extracellular vesicle microRNA in acute lung injury].
    Ren Y; Chen M; Liu X; Feng B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 May; 33(5):633-637. PubMed ID: 34112309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.